**Company Overview**

Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory conditions including, serious lung infections, pulmonary hypertension and gaseous NO for the treatment of solid tumors. The Beyond Air NO Delivery System can generate up to 400 ppm of NO for delivery either continuously or for a fixed amount of time and has the ability to either titrate dose on demand or maintain a constant dose. The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for lower respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its revolutionary NO Generator and Delivery System in clinical trials for the treatment of bronchiolitis and severe lung infections such as nontuberculous mycobacteria (NTM) and COVID-19. Beyond Air have also developed a proprietary system for delivering gaseous nitric oxide at high concentrations to treat solid tumors.

**Beyond Air® Schedules First Fiscal Quarter 2022 Financial Results Conference Call and Webcast**

Jul 20 2021, 7:30 AM EDT

**Beyond Air® Announces Participation at Upcoming Virtual Investor Conferences in July 2021**

Jul 8 2021, 4:14 PM EDT

**Beyond Air® Reports Financial Results for Fourth Fiscal Quarter and Year-End 2021**

Jun 10 2021, 4:05 PM EDT

**Stock Overview**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>XAIR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exchange</td>
<td>Nasdaq</td>
</tr>
<tr>
<td>Market Cap</td>
<td>181.25m</td>
</tr>
<tr>
<td>Last Price</td>
<td>$7.79</td>
</tr>
<tr>
<td>52-Week Range</td>
<td>$4.62 - $9.30</td>
</tr>
</tbody>
</table>

**Investor Relations**

<table>
<thead>
<tr>
<th>LifeSci Advisors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corey Davis</td>
</tr>
<tr>
<td>250 West 55th Street</td>
</tr>
<tr>
<td>34th Floor</td>
</tr>
<tr>
<td>New York, NY 10019</td>
</tr>
<tr>
<td>T: 1-646-597-6989</td>
</tr>
<tr>
<td><a href="mailto:cdavis@lifesciadvisors.com">cdavis@lifesciadvisors.com</a></td>
</tr>
</tbody>
</table>

**Management Team**

**Steve Lisi**
CEO and Chairman of the Board

**Amir Avniel**
President and Chief Operating Officer

**Duncan Fatkin**
Chief Commercial Officer

**Douglas Beck**
Chief Financial Officer

**Frederick Montgomery, PhD**
Vice President of Medical Systems

**Michael Gaul**
Senior Vice President, Operations

**Rebecca Van Doren**
Head of Sales

**Kori-Ann Taylor**
Head of Marketing

**Beyond Air Inc.**
825 East Gate Boulevard
Suite 320
Garden City, NY 11530

**Disclaimer**

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company’s SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.